Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 30;15(1):220.
doi: 10.3390/cancers15010220.

Controversies in the Front-Line Treatment of Systemic Peripheral T Cell Lymphomas

Marc Sorigue  1 , Outi Kuittinen  2   3   4
Affiliations
Review

Controversies in the Front-Line Treatment of Systemic Peripheral T Cell Lymphomas

Marc Sorigue et al. Cancers (Basel). .

Abstract

Systemic peripheral T cell lymphomas (PTCL) are a rare and clinically and biologically heterogeneous group of disorders with scarce and generally low-quality evidence guiding their management. In this manuscript, we tackle the current controversies in the front-line treatment of systemic PTCL including (1) whether CNS prophylaxis should be administered; (2) whether CHOEP should be preferred over CHOP; (3) what role brentuximab vedotin should have; (4) whether stem cell transplant (SCT) consolidation should be used and whether autologous or allogeneic; (5) how should molecular subtypes (including DUSP22 or TP63-rearranged ALCL or GATA3 or TBX21 PTCL, NOS) impact therapeutic decisions; and (6) whether there is a role for targeted agents beyond brentuximab vedotin.

Keywords: CHOP; T cell lymphoma; brentuximab; etoposide; stem cell transplant.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Campo E., Jaffe E.S., Cook J.R., Quintanilla-Martinez L., Swerdlow S.H., Anderson K.C., Brousset P., Cerroni L., de Leval L., Dirnhofer S., et al. The International Consensus Classification of Mature Lymphoid Neoplasms: A report from the Clinical Advisory Committee. Blood. 2022;140:1229–1253. doi: 10.1182/blood.2022015851. - DOI - PMC - PubMed
    1. Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J., Vardiman J.W. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow S.H., editor. International Agency for Research on Cancer; Lyon, France: 2017.
    1. Brink M., Meeuwes F.O., van der Poel M.W.M., Kersten M.J., Wondergem M., Mutsaers P.G.N.J., Böhmer L.H., Woei-A-Jin F.S.H., Visser O., Oostvogels R., et al. Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: A population-based cohort study. Blood. 2022;140:1009–1019. - PMC - PubMed
    1. Bachy E., Camus V., Thieblemont C., Sibon D., Casasnovas R.-O., Ysebaert L., Damaj G., Guidez S., Pica G.M., Kim W.S., et al. Romidepsin Plus CHOP Versus CHOP in Patients with Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA) J. Clin. Oncol. 2022;40:242–251. doi: 10.1200/JCO.21.01815. - DOI - PubMed
    1. Vose J., Armitage J., Weisenburger D. International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J. Clin. Oncol. 2008;26:4124–4130. - PubMed